Researchers have found that bevacizumab-induced hypertension may be a predictive marker of improved outcomes in patients with recurrent glioblastoma who are treated with bevacizumab.
Baseline hypertension and BMI can affect worsening hypertension among patients administered vascular endothelial growth factor signaling pathway inhibitors, according to research presented at the 2014 ASCO Annual Meeting.
The mechanisms underlying VEGF-inhibitor-induced hypertension need to be better understood and clear guidelines and improved management are needed, according to a recent review.
Non-Hispanic whites treated long term with antihypertensives have increased odds of lip cancer.
Is there any information about a link between lisinopril and breast cancer recurrence?
